Skip to main content

Diego Baranda Martínez-Abasca

I did my Bachelor in Biology at the UIB and I subsequently studied the Master's in Molecular Biotechnology at the University of Barcelona (UB). Before arriving at the VHIR I had an internship contract at the Institute of BioEngineering of Catalonia (IBEC) and I carried out a research stay at the Institute of Molecular Biology of Barcelona (IBMB - Spanish National Research Council, CSIC). The obtention of a University Teacher Training grant (FPU) allowed me to join the VHIR in order to carry out my doctoral thesis in the Drug Delivery and Targeting group. My project is based on the development of an alternative therapy for pancreatic cancer using genetically modified extracellular vesicles (EVs). I'm also working on other projects that pursue the development of the use of EVs for the treatment of minority diseases. In addition, I continue my training with the doctoral courses of the UB and I participate in scientific dissemination activities organized by the VHIR, among other things. Thanks for your interest :)

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Diego Baranda Martínez-Abasca

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

I did my Bachelor in Biology at the UIB and I subsequently studied the Master's in Molecular Biotechnology at the University of Barcelona (UB). Before arriving at the VHIR I had an internship contract at the Institute of BioEngineering of Catalonia (IBEC) and I carried out a research stay at the Institute of Molecular Biology of Barcelona (IBMB - Spanish National Research Council, CSIC). The obtention of a University Teacher Training grant (FPU) allowed me to join the VHIR in order to carry out my doctoral thesis in the Drug Delivery and Targeting group. My project is based on the development of an alternative therapy for pancreatic cancer using genetically modified extracellular vesicles (EVs). I'm also working on other projects that pursue the development of the use of EVs for the treatment of minority diseases. In addition, I continue my training with the doctoral courses of the UB and I participate in scientific dissemination activities organized by the VHIR, among other things. Thanks for your interest :)

Bachelor in Biology UIB. Erasmus at the University of Radboud, Nijmegen (Netherlands). Bachelor¡s thesis at the Balearic Islands Health Research Institute (IdISBa). Graduated in 2019, average grade of 8.92. Granted with the Scolarship for the Promotion of Academic Excellence 2018-2019 (GOIB).
Master of Molecular Biotechnology at the University of Barcelona (UB). Master's thesis at the Institute of BioEngineering of Barcelona (IBEC), granted with the IBEC Master Program Scholarship 2019. Graduated in 2020, average grade of 9.
Research stay at the Institute of Molecular Biology of Barcelona (IBMB), Spanish National Research Council (CSIC), granted with the JAE Intro 2020 Fellowship from the Ministry of Science and Innovation of Spain.
PhD at the Drug Delivery and Targeting (DDT) group of the VHIR. Obtention of a grant for University Teacher Training (FPU) awarded by the spanish Ministry of Universities. Development of a nanomedical alternative therapy for pancreatic cancer using genetically modified extracellular vesicles (EVs).
Level C2 in English issued by Cambridge English (CAE). Level B1 in French issued by the Official School of Languages ​​(EOI).

Projects

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo.

IP: Joaquin Seras Franzoso
Collaborators: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI22/01301
Duration: 01/01/2023 - 31/12/2025

Vehiculización de proteínas terapéuticas mediante vesículas extracelulares para el tratamiento de enfermedades huérfanas

IP: Vehiculización de proteínas terapéuticas mediante vesículas extracelulares para el tratamiento de enfermedades huérfanas
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 59223.42
Reference: FPU20/04210
Duration: 01/12/2021 - 31/03/2025

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Enrique Jose Montagut Cañete

Enrique Jose Montagut Cañete

Read more
Victor  Barro  Ojeda

Victor Barro Ojeda

Reconstructive Surgery of the Locomotor System
Read more
Esperanza Medina Gutierrez

Esperanza Medina Gutierrez

Research technician
Molecular Medical Imaging
Read more
Eduard Mogas Viñas

Eduard Mogas Viñas

Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.